Novel cancer therapies targeting key cancer pathways
We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.
OUR COMPANY
Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
OUR SCIENCE
Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.
LATEST NEWS
| 10/12/2018 | Interim Durability Analysis of PTX-200 Breast Cancer Study | |
| 20/11/2018 | Results of Annual General Meeting | |
| 20/11/2018 | AGM Presentation | |
| 31/10/18 | September 2018 Appendix 4C - Quarterly | |
| 29/10/2018 | PTX Appoints Former Array BioPharma Executive to Key Role | |
| 19/10/2018 | Notice of Annual General Meeting/Proxy Form |